Terms: = Lung cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
238 results:
1. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer.
Li Y; Sharma A; Schmidt-Wolf IGH
Mol Cancer; 2024 Apr; 23(1):80. PubMed ID: 38659003
[TBL] [Abstract] [Full Text] [Related]
2. Implantable car T cell factories enhance solid tumor treatment.
Pandit S; Agarwalla P; Song F; Jansson A; Dotti G; Brudno Y
Biomaterials; 2024 Jul; 308():122580. PubMed ID: 38640784
[TBL] [Abstract] [Full Text] [Related]
3. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.
Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
[TBL] [Abstract] [Full Text] [Related]
4. Anti-CD30 car T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30
Grover NS; Hucks G; Riches ML; Ivanova A; Moore DT; Shea TC; Seegars MB; Armistead PM; Kasow KA; Beaven AW; Dittus C; Coghill JM; Jamieson KJ; Vincent BG; Wood WA; Cheng C; Morrison JK; West J; Cavallo T; Dotti G; Serody JS; Savoldo B
Lancet Haematol; 2024 May; 11(5):e358-e367. PubMed ID: 38555923
[TBL] [Abstract] [Full Text] [Related]
5. The prognostic value and model construction of inflammatory markers for patients with non-small cell lung cancer.
Xu W; Liu X; Yan C; Abdurahmane G; Lazibiek J; Zhang Y; Cao M
Sci Rep; 2024 Mar; 14(1):7568. PubMed ID: 38555313
[TBL] [Abstract] [Full Text] [Related]
6. Drug-induced interstitial lung disease: a narrative review of a clinical conundrum.
Harrison M; Kavanagh G; Corte TJ; Troy LK
Expert Rev Respir Med; 2024; 18(1-2):23-39. PubMed ID: 38501199
[TBL] [Abstract] [Full Text] [Related]
7. [Severe complications of systemic treatment in thoracic oncology].
Berghmans T; Brandão M; Ilzkovitz M; Meert AP
Rev Mal Respir; 2024 Apr; 41(4):317-324. PubMed ID: 38461088
[TBL] [Abstract] [Full Text] [Related]
8. Rejuvenated iPSC-derived GD2-directed carT Cells Harbor Robust Cytotoxicity Against Small Cell lung cancer.
Kinoshita S; Ishii M; Ando J; Kimura T; Yamaguchi T; Harada S; Takahashi F; Nakashima K; Nakazawa Y; Yamazaki S; Ohshima K; Takahashi K; Nakauchi H; Ando M
Cancer Res Commun; 2024 Mar; 4(3):723-737. PubMed ID: 38380966
[TBL] [Abstract] [Full Text] [Related]
9. Targeting Antheraea pernyi silk fibroin modified dual-gene coexpressing vector enhances gene transport and promotes lung tumor suppression.
Qu J; Xia Z; Liu Y; Li M; Xie Y
Int J Biol Macromol; 2024 Mar; 262(Pt 2):130074. PubMed ID: 38342259
[TBL] [Abstract] [Full Text] [Related]
10. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy against lung cancer Is Augmented by Combining Aberrantly N-Glycosylated T Cells with a Chimeric Antigen Receptor Targeting Fragile X Mental Retardation 1 Neighbor.
Toyofuku T; Ishikawa T; Nojima S; Kumanogoh A
J Immunol; 2024 Mar; 212(5):917-927. PubMed ID: 38214607
[TBL] [Abstract] [Full Text] [Related]
12. Effects of methionine deficiency on B7H3-DAP12-car-T cells in the treatment of lung squamous cell carcinoma.
Yu T; Nie FQ; Zhang Q; Yu SK; Zhang ML; Wang Q; Wang EX; Lu KH; Sun M
Cell Death Dis; 2024 Jan; 15(1):12. PubMed ID: 38182561
[TBL] [Abstract] [Full Text] [Related]
13. Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities.
Zhou D; Gong Z; Wu D; Ma C; Hou L; Niu X; Xu T
J Hematol Oncol; 2023 Dec; 16(1):121. PubMed ID: 38104104
[TBL] [Abstract] [Full Text] [Related]
14. HER2 and HLA-A*02 dual car-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity.
Bassan D; Weinberger L; Yi J; Kim T; Weist MR; Adams GB; Foord O; Chaim N; Tabak S; Bujanover N; Lopesco Y; Vucci K; Schnair C; Levy-Knafo L; Kendall RL; Calzone FJ; Sharbi-Yunger A
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38097342
[TBL] [Abstract] [Full Text] [Related]
15. Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
Yoshimoto S; Chester N; Xiong A; Radaelli E; Wang H; Brillantes M; Gulendran G; Glassman P; Siegel DL; Mason NJ
MAbs; 2023; 15(1):2287250. PubMed ID: 38047502
[TBL] [Abstract] [Full Text] [Related]
16. CD44v6 specific car-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.
Ciulean IS; Fischer J; Quaiser A; Bach C; Abken H; Tretbar US; Fricke S; Koehl U; Schmiedel D; Grunwald T
Front Immunol; 2023; 14():1290488. PubMed ID: 38022580
[TBL] [Abstract] [Full Text] [Related]
17. Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement.
Assié JB; Jean D
Expert Opin Ther Targets; 2023; 27(11):1059-1069. PubMed ID: 37902459
[TBL] [Abstract] [Full Text] [Related]
18. A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity.
Lee DH; Ahn H; Sim HI; Choi E; Choi S; Jo Y; Yun B; Song HK; Oh SJ; Denda-Nagai K; Park CS; Irimura T; Park Y; Jin HS
J Exp Clin Cancer Res; 2023 Oct; 42(1):272. PubMed ID: 37858248
[TBL] [Abstract] [Full Text] [Related]
19. Targeting CDH17 with Chimeric Antigen Receptor-Redirected T Cells in Small Cell lung cancer.
Tian W; Zhao J; Wang W
Lung; 2023 Oct; 201(5):489-497. PubMed ID: 37823901
[TBL] [Abstract] [Full Text] [Related]
20. Tislelizumab plus chemotherapy vs. pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials.
Messori A; Rivano M; Chiumente M; Mengato D
Chin Clin Oncol; 2023 Oct; 12(5):50. PubMed ID: 37817505
[TBL] [Abstract] [Full Text] [Related]
[Next]
